Rapamycin manufacturer CAS NO.53123-88-9

LIDE PHARMACEUTICALS LIMITED is a professional chemicals and APIs leading manufacturer in China.  Our core business line covers APIs, Intermediates, Herb extract, etc.

We are specialized in chemical synthesis, process development of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and rare chemicals. We also accept custom synthesis project and contract research services.

R&D strength:

We have well equipped chemicals and instrumental laboratories with modern instruments such as HPLC,GC,IR,UV,NMR,LC-MS etc.

At present, we are selling it with good discount for immediate delivery !  BOOKING TO HASTEN ! 

(1) Company profile:

Company profile: Lide pharmaceuticals limited

Main products: APIs; Intermediate and other fine chemical products; Piperazine series; Custom Synthesis.

Main Markets: North America; South America; Eastern Europe; Southeast Asia; Africa Oceania; Mid East; Eastern Asia; Western Europe, etc.

(2) Product:

Product Name: Sirolimus, Rapamycin

CAS No.: 53123-88-9

Molecular Formula: C51H79NO13

Molecular Weight: 914.18 

Appearance: White to off-white powder

Specification: 98%-102%

(3) Application: 

Rapamycin is a triene macrolide discovered in 1995 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapi Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumour and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumour growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.